1. Health, U.D.o. and H. Services . Common Terminology Criteria for Adverse Events (CTCAE) v5.0. (accessed 27 November 2017).
Google Scholar2. Nuno-Gonzalez, A, Magaletsky, K, Feito Rodríguez, M, et al. Palmoplantar erythrodysestesia: a diagnostic sign of COVID-19. J Eur Acad Dermatol Venereol 2020; 35: 247–249.
Google Scholar | Medline3. Zuehlke, RL . Erythematous eruption of the palms and soles associated with mitotane therapy. Dermatologica 1974; 148: 90–92.
Google Scholar | Crossref | Medline4. Degen, A, Alter, M, Schenck, F, et al. The hand-foot-syndrome associated with medical tumor therapy–classification and management. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 2010; 8: 652–661.
Google Scholar | Crossref | Medline5. Baack, BR, Burgdorf, WHC. Chemotherapy-induced acral erythema. J Am Acad Dermatol. 1991; 24: 457–461.
Google Scholar | Crossref | Medline | ISI6. Vahab, A, Hakvani, M, Ehsan, H, et al. Paclitaxel-Induced palmar-plantar erythrodysesthesia. Cureus 2020; 12: 11507.
Google Scholar7. Lipworth, AD, Robert, C, ZHU, AX. Hand-foot syndrome (hand-foot skin reaction,palmar-plantar erythrodysesthesia):focus on sorafenib and sunitinib. Oncology 2009; 77: 257–271.
Google Scholar | Crossref | Medline | ISI8. Gilbar, P, Pharm, B, PallC, M. Palmar-plantar erythrodysesthesia. J Oncol Pharm Practice 2003; 9: 137–150.
Google Scholar | SAGE Journals9. Wang, JZ, Cowley, A, McLellan, BN. Differentiating hand-foot syndrome from tinea in patients receiving chemotherapy. Acta Oncol (Madr) 2016; 55: 1061–1064.
Google Scholar | Crossref | Medline10. Naranjo, CA, Busto, U, Sellers, EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981 Aug; 30: 239–245.
Google Scholar | Crossref | Medline11. Brazzelli, V, Grasso, V, Borroni, G. Imatinib, dasatinib and nilotinib: a review of adverse cutaneous reactions with emphasis on our clinical experience. J Eur Acad Dermatol Venereol 2013; 27: 1471–1480.
Google Scholar | Crossref | Medline